Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2

NCT: NCT07593209 · RECRUITING

NCT IDNCT07593209
StatusRECRUITING
Start Date2026-05-01
Completion2027-12-31

Brief Summary

Purpose Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase overexpressed in various solid tumors and associated with tumor progression, metastasis, and poor prognosis. However, noninvasive imaging tools for assessing EphA2 expression in vivo remain limited. This study aims to develop a novel 68Ga-labeled EphA2-targeting positron emission tomography (PET) tracer for specific imaging of EphA2-positive malignancies.

Frequently Asked Questions

What is First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2?

First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2 is a clinical trial registered under NCT07593209. Current status: RECRUITING.

What is the status of NCT07593209?

The current status of NCT07593209 (First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2) is: RECRUITING.

When did First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2 start?

First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2 started on 2026-05-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑